95 related articles for article (PubMed ID: 10694841)
41. Increased serum levels of soluble CD14 indicate stable multiple sclerosis.
Lutterotti A; Kuenz B; Gredler V; Khalil M; Ehling R; Gneiss C; Egg R; Deisenhammer F; Berger T; Reindl M
J Neuroimmunol; 2006 Dec; 181(1-2):145-9. PubMed ID: 17046070
[TBL] [Abstract][Full Text] [Related]
42. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment.
Lindquist S; Hassinger S; Lindquist JA; Sailer M
Mult Scler; 2011 Jul; 17(7):851-66. PubMed ID: 21561957
[TBL] [Abstract][Full Text] [Related]
43. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis.
Börnsen L; Khademi M; Olsson T; Sørensen PS; Sellebjerg F
Mult Scler; 2011 Jan; 17(1):32-42. PubMed ID: 20921238
[TBL] [Abstract][Full Text] [Related]
44. Benign multiple sclerosis is characterized by a stable neuroimmunologic network.
Haase CG; Faustmann PM
Neuroimmunomodulation; 2004; 11(4):273-7. PubMed ID: 15249735
[TBL] [Abstract][Full Text] [Related]
45. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
46. Expansion of CD4+CD28- T cells producing high levels of interferon-{gamma} in peripheral blood of patients with multiple sclerosis.
Miyazaki Y; Iwabuchi K; Kikuchi S; Fukazawa T; Niino M; Hirotani M; Sasaki H; Onoé K
Mult Scler; 2008 Sep; 14(8):1044-55. PubMed ID: 18573819
[TBL] [Abstract][Full Text] [Related]
47. Walk ratio (step length/cadence) as a summary index of neuromotor control of gait: application to multiple sclerosis.
Rota V; Perucca L; Simone A; Tesio L
Int J Rehabil Res; 2011 Sep; 34(3):265-9. PubMed ID: 21629125
[TBL] [Abstract][Full Text] [Related]
48. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
[TBL] [Abstract][Full Text] [Related]
49. Stimulated peripheral production of interferon-gamma is related to fatigue and depression in multiple sclerosis.
Pokryszko-Dragan A; Frydecka I; Kosmaczewska A; Ciszak L; Bilińska M; Gruszka E; Podemski R; Frydecka D
Clin Neurol Neurosurg; 2012 Oct; 114(8):1153-8. PubMed ID: 22425464
[TBL] [Abstract][Full Text] [Related]
50. No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosis.
Petereit HF; Reske D; Pukrop R; Maas-Enriquez M; Japp G; Jongen PJ; Kölmel HW; Merkelbach S; Hartung HP; Heiss WD; Hommes OR
Mult Scler; 2006 Feb; 12(1):66-71. PubMed ID: 16459721
[TBL] [Abstract][Full Text] [Related]
51. T2 lesions and rate of progression of disability in multiple sclerosis.
Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
[TBL] [Abstract][Full Text] [Related]
52. [Multiple sclerosis vaccine: possibilities of the use of dendritic cells immunomodulatory potential].
Odinak MM; Bisaga GN; Chirskii VS; Pashchenkov MV; Baldueva IA; Moiseenko VM; Nekhaeva TL; Kalinina NM; Davydova NI; Bychkova NV; Pozdnyakov AV
Voen Med Zh; 2016 Apr; 337(4):31-5. PubMed ID: 27416719
[TBL] [Abstract][Full Text] [Related]
53. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL
Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027
[TBL] [Abstract][Full Text] [Related]
54. Interferon gamma producing blood lymphocytes are decreased by interferon beta therapy in patients with multiple sclerosis.
Petereit HF; Bamborschke S; Esse AD; Heiss WD
Mult Scler; 1997 Jun; 3(3):180-3. PubMed ID: 9310963
[TBL] [Abstract][Full Text] [Related]
55. Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosis.
Petereit HF; Pukrop R; Fazekas F; Bamborschke SU; Röpele S; Kölmel HW; Merkelbach S; Japp G; Jongen PJ; Hartung HP; Hommes OR
J Neurol Sci; 2003 Feb; 206(2):209-14. PubMed ID: 12559513
[TBL] [Abstract][Full Text] [Related]
56. A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis.
Pasquali L; Lucchesi C; Pecori C; Metelli MR; Pellegrini S; Iudice A; Bonuccelli U
J Neuroimmunol; 2015 Jan; 278():53-9. PubMed ID: 25595252
[TBL] [Abstract][Full Text] [Related]
57. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
van der Voort LF; Gilli F; Bertolotto A; Knol DL; Uitdehaag BM; Polman CH; Killestein J
Arch Neurol; 2010 Apr; 67(4):402-7. PubMed ID: 20142519
[TBL] [Abstract][Full Text] [Related]
58. Correlation between disease severity and in vitro cytokine production mediated by MSRV (multiple sclerosis associated retroviral element) envelope protein in patients with multiple sclerosis.
Rolland A; Jouvin-Marche E; Saresella M; Ferrante P; Cavaretta R; Créange A; Marche P; Perron H
J Neuroimmunol; 2005 Mar; 160(1-2):195-203. PubMed ID: 15710473
[TBL] [Abstract][Full Text] [Related]
59. Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor.
Petereit HF; Lindemann H; Schoppe S
Mult Scler; 2003 Feb; 9(1):16-20. PubMed ID: 12617262
[TBL] [Abstract][Full Text] [Related]
60. Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability.
Flachenecker P; Reiners K; Krauser M; Wolf A; Toyka KV
Mult Scler; 2001 Oct; 7(5):327-34. PubMed ID: 11724449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
